Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $12.70 and traded as low as $12.45. Astria Therapeutics shares last traded at $12.58, with a volume of 3,199,300 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ATXS. Cantor Fitzgerald downgraded Astria Therapeutics from an “overweight” rating to a “neutral” rating in a report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Astria Therapeutics in a research report on Wednesday, January 21st. Finally, Lifesci Capital cut shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Two equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Astria Therapeutics presently has a consensus rating of “Hold” and an average target price of $24.50.

Astria Therapeutics Stock Up 0.6%

The company’s 50 day moving average is $12.70 and its 200 day moving average is $10.86. The firm has a market capitalization of $718.13 million, a price-to-earnings ratio of -5.88 and a beta of 0.01.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Astria Therapeutics during the fourth quarter worth about $25,000. Strs Ohio acquired a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $45,000. Russell Investments Group Ltd. boosted its position in shares of Astria Therapeutics by 10,311.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 3,506 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Astria Therapeutics by 22.3% in the third quarter. Farther Finance Advisors LLC now owns 6,693 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,222 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Astria Therapeutics during the fourth quarter valued at approximately $88,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.